Integra LifeSciences Expects FY24 Revenue of $1.672B-$1.687B (Prior $1.603B-$1.618B) Vs $1.616B Est, Adj EPS of $3.01-$3.11 (Prior $3.15-$3.25) Vs $3.19 Est
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences has updated its FY24 revenue and adjusted EPS forecasts to $1.672B-$1.687B and $3.01-$3.11, respectively, from prior forecasts of $1.603B-$1.618B and $3.15-$3.25. This update reflects an 8.4%-9.4% reported growth and 3.3%-4.3% organic growth, considering the Acclarent acquisition and a $10M revenue adjustment from SurgiMend and PriMatrix relaunches.
May 06, 2024 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Integra LifeSciences has raised its FY24 revenue forecast to $1.672B-$1.687B and adjusted its EPS forecast to $3.01-$3.11, indicating a positive growth outlook.
The upward revision in revenue forecast suggests a positive growth trajectory for Integra LifeSciences, primarily due to the Acclarent acquisition and strategic product relaunches. The slight adjustment in EPS reflects the company's realistic earnings expectations amidst these changes. This news is likely to be viewed positively by investors, as it indicates management's confidence in the company's growth and operational efficiency.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100